17-Apr-2026
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
TipRanks (Thu, 16-Apr 5:12 PM ET)
Market Chameleon (Tue, 14-Apr 5:20 AM ET)
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
TipRanks (Tue, 14-Apr 9:06 AM ET)
Globe Newswire (Tue, 14-Apr 8:00 AM ET)
Globe Newswire (Tue, 7-Apr 8:00 AM ET)
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Globe Newswire (Wed, 18-Mar 8:00 AM ET)
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Globe Newswire (Mon, 9-Mar 7:30 AM ET)
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
Globe Newswire (Thu, 12-Feb 8:00 AM ET)
CRBP’s Phase 1a Results Reveal Favorable Safety Profile and Notable Early Weight Loss with CRB-913
Market Chameleon (Thu, 11-Dec 2:06 AM ET)
CRBP Announces $75 Million Public Offering: Focus on Advancing Oncology and Obesity Pipeline
Market Chameleon (Fri, 31-Oct 4:20 AM ET)
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Corbus Pharmaceuticals Holdings trades on the NASDAQ stock market under the symbol CRBP.
As of April 17, 2026, CRBP stock price climbed to $10.59 with 538,723 million shares trading.
CRBP has a beta of 1.63, meaning it tends to be more sensitive to market movements. CRBP has a correlation of 0.07 to the broad based SPY ETF.
CRBP has a market cap of $187.83 million. This is considered a Micro Cap stock.
Last quarter Corbus Pharmaceuticals Holdings reported $0 in Revenue and -$1.25 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.41.
In the last 3 years, CRBP traded as high as $61.90 and as low as $3.03.
The top ETF exchange traded funds that CRBP belongs to (by Net Assets): VTI, VXF, DFAS, IWC, OZEM.
CRBP has outperformed the market in the last year with a return of +75.6%, while the SPY ETF gained +36.3%. In the last 3 month period, CRBP beat the market returning +27.3%, while SPY returned +2.9%. However, in the most recent 2 weeks CRBP has underperformed the stock market by returning +4.1%, while SPY returned +8.3%.
CRBP support price is $9.62 and resistance is $10.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBP shares will trade within this expected range on the day.